KineMed Announces Agreement With MedImmune
News May 22, 2013
KineMed Inc. announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc).
Cellular prion protein is found in healthy people, but this protein is known to have altered conformation and function in several neurodegenerative conditions including Creutzfeldt–Jakob disease and fatal familial insomnia. Recent research has also demonstrated that the prion protein may be a key component of Alzheimer's disease. KineMed’s platform technology will allow MedImmune to track the prion protein, providing insight into how an antibody directed at PrPc will affect the turnover and expression of the protein at the cell surface.
“We are very pleased to work with MedImmune in the search for new and effective treatments for neurodegenerative diseases,” said Dr. Ravi Kiron, Chief Business Officer of KineMed. “The growing toll of neurodegenerative disease in the aging global population is an enormous burden for patients, healthcare providers, and healthcare systems world-wide. KineMed is committed to partnering with innovative biotech companies like MedImmune to help accelerate the discovery and approval of new and effective therapies for neurodegenerative disease.”
The MedImmune scientists working on this project are part of the AstraZeneca Neuroscience Innovative Medicines Unit.
Can You Eat Cells? Computer Model Predicts Organisms that Use PhagocytosisNews
A computer model developed by Museum researchers may provide new insight into the origins of phagocytosis, the process by which single-celled organisms “eat” other cells as a means of absorbing nutrients or eliminating pathogens.READ MORE
‘Lipid Asymmetry’ Plays Key Role in Activating Immune CellsNews
Regulating the lipid and physical asymmetry of a cell’s membrane is critical to immune cell function, and researchers have now shown that by preventing loss of membrane asymmetry it’s possible to control the immune response.READ MORE
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE